BENRALIZUMAB and COUGH

Overview

COUGH is the #5 most commonly reported adverse reaction for BENRALIZUMAB, manufactured by AstraZeneca Pharmaceuticals LP. There are 944 FDA adverse event reports linking BENRALIZUMAB to COUGH. This represents approximately 3.0% of all 31,657 adverse event reports for this drug.

Patients taking BENRALIZUMAB who experience cough should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.

Reporting Frequency

COUGH is a less commonly reported adverse event for BENRALIZUMAB, but still significant enough to appear in the safety profile.

Other Side Effects of BENRALIZUMAB

In addition to cough, the following adverse reactions have been reported for BENRALIZUMAB:

• ASTHMA — 2,775 reports
• DYSPNOEA — 1,802 reports
• DEATH — 1,437 reports
• DRUG INEFFECTIVE — 1,418 reports
• HEADACHE — 874 reports
• PRODUCT DOSE OMISSION ISSUE — 825 reports
• PNEUMONIA — 823 reports
• WHEEZING — 692 reports
• FATIGUE — 592 reports
• MALAISE — 565 reports

Other Drugs Associated with COUGH

The following drugs have also been linked to cough in FDA adverse event reports:

Does BENRALIZUMAB cause COUGH?

COUGH has been reported as an adverse event in 944 FDA reports for BENRALIZUMAB. This does not prove causation, but indicates an association observed in post-market surveillance data.

How common is COUGH with BENRALIZUMAB?

COUGH accounts for approximately 3.0% of all adverse event reports for BENRALIZUMAB, making it a notable side effect.

What should I do if I experience COUGH while taking BENRALIZUMAB?

If you experience cough while taking BENRALIZUMAB, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.

Related Pages